Illumina and Ovation.io have announced a groundbreaking collaboration to create the largest commercially available clinical multiomic dataset from 25,000 patients treated with GLP-1 receptor agonist therapies. This initiative aims to provide the pharmaceutical community with unprecedented resources to accelerate the discovery and development of new and improved GLP-1-based treatments.
The collaboration addresses the significant variability in patient response to GLP-1 therapies, with studies indicating that a substantial portion of individuals do not respond effectively. By integrating phenotypic, whole-genome sequencing, and proteomic data, the dataset seeks to unravel the molecular mechanisms underlying GLP-1 response and resistance. This deeper understanding could pave the way for new therapeutic indications, novel biomarkers to predict patient response, and the identification of drug targets for non-responsive populations.
Todd Christian, Senior Vice President at Illumina, emphasized the growing impact of multiomic insights in addressing complex diseases like metabolic disorders. Marty Miller, Chief Revenue Officer of Ovation, highlighted the unique scale and inclusion of proteomics in this dataset, aiming to equip the pharmaceutical industry with crucial insights into the varying effectiveness and side effects of GLP-1 receptor agonists.
The initiative leverages Illumina’s advanced NGS technologies for whole-genome sequencing and protein profiling of a subset of samples using the Illumina Protein Prep (IPP) assay. This will enable the discovery of protein quantitative trait loci (pQTLs), linking genetic variations to protein expression and disease phenotypes. Ovation.io contributes its extensive biobank of de-identified patient samples with rich clinical data.
This collaboration builds upon a previous agreement between Illumina and Ovation in 2024, focusing on leveraging genomic data to overcome drug development challenges. The GLP-1 dataset is a significant expansion of these efforts, with potential for future scaling and the creation of similar datasets for other disease areas. This initiative positions multiomic data as a critical tool in accelerating the next generation of precision therapies.